Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
2019 · Molecular Cancer · 1,145 citations
https://doi.org/10.1186/s12943-019-1091-2
L
Linping Xu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
72
Papers
3.1K
Citations
21
h-index
34
i10-index
Linping Xu is an academic researcher from Henan Cancer Hospital. The author has contributed to research in topics: Immune Cell Function and Interaction & Pain Mechanisms and Treatments & Cancer-related molecular mechanisms research. The author has an h-index of 21, co-authored 62 publications.
Papers by this author
worksRegulation of PD-L1 expression in the tumor microenvironment
2021 · Journal of Hematology & Oncology · 615 citations
https://doi.org/10.1186/s13045-020-01027-5
SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
2022 · Journal of Translational Medicine · 61 citations
https://doi.org/10.1186/s12967-022-03342-6
Paclitaxel Induces Sex-biased Behavioral Deficits and Changes in Gene Expression in Mouse Prefrontal Cortex
2019 · Neuroscience · 35 citations
https://doi.org/10.1016/j.neuroscience.2019.11.031
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
2024 · Drug Resistance Updates · 32 citations
https://doi.org/10.1016/j.drup.2024.101068
Genetic editing and interrogation with Cpf1 and caged truncated pre-tRNA-like crRNA in mammalian cells
2018 · Cell Discovery · 18 citations
https://doi.org/10.1038/s41421-018-0035-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat